Fig. 8: Sorafenib reduces cell proliferation in Huh7 cells, which is not affected by the combination with TRAIL or ABT-737. | Cell Death & Disease

Fig. 8: Sorafenib reduces cell proliferation in Huh7 cells, which is not affected by the combination with TRAIL or ABT-737.

From: BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment

Fig. 8

A Analyses of proliferation inhibition by immunohistochemical assessment of Ki67-positive (red) Huh7 cells treated for 8 h with sorafenib (7.5 µg/ml) and/or ABT-737 (5 µM). Sorafenib but not ABT-737 alone significantly reduced cell proliferation. The combination of sorafenib and ABT-737 did not further increase inhibition of proliferation as compared to sorafenib alone. B TRAIL treatment (50 ng/ml) of Huh7 cells did not significantly affect cell proliferation. The combined treatment of Huh7 cells with sorafenib and TRAIL for 8 h did not further inhibit cell proliferation compared to sorafenib alone. Results of four (A, B) independent experiments are shown. Significances indicated above the bars refer to control. *p < 0.05; n.s. non-significant; scale bars = 100 µm.

Back to article page